ClinicalThought

Share

Program Content

Activities

  • NSCLC: A Look Ahead
    Immunotherapy and Targeted Therapy in NSCLC: Where Are We Going in 2018?
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 28, 2017

  • Managing <i>ALK</i>+ NSCLC
    My Approach for Managing Patients With Progressive ALK-Positive NSCLC
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 22, 2018

  • New Nivolumab Dosing
    A New Nivolumab Dosing Option for Our Patients With Advanced NSCLC
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 16, 2018

  • Lung Cancer at AACR 2018
    First-line Therapy in NSCLC: What You Need to Know From AACR 2018
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2018

  • Progression After New ICI Options
    New Immunotherapy Paradigms Earlier in NSCLC: What Comes After Progression?
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 26, 2018

  • <i>ALK</i>+ NSCLC: Brigatinib
    My Thoughts on First-line Treatment for ALK-Positive NSCLC Today
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 24, 2018

Faculty

cover img faculity

Lyudmila Bazhenova, MD

Associate Clinical Professor of Medicine
Division of Hematology-Oncology
University of California, San Diego
Medical Director, UC San Diego Moores Cancer Center Infusion Center
San Diego, California

cover img faculity

Edward B. Garon, MD, MS

Professor of Medicine
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

cover img faculity

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

cover img faculity

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Provided by

ProCE Banner

Supporters

AstraZeneca

Bristol Myers Squibb

Celgene TEXT Only

Genentech TEXT Only

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Takeda Oncology